Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic...(ty of Vidaza may be discovered upon furt...)

Date:8/29/2007

ty of Vidaza may be discovered upon further analysis of data from that trail or analysis of data from other ongoing Vidaza clinical trials; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; and the failure of third-party manufacturers to produce the product volumes required on a timely basis. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

'/>"/>

SOURCE Pharmion Corporation Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Mirus granted European patent for gene therapy
2. Platypus granted new liquid crystal patent
3. WARF Granted New Antibiotics Patent
4. Identity theft start up has fast-track growth plans
5. In pursuit of capital, be sure to track your private offering
6. Jellyfish partners for sales tracking technology
7. Medical College team creates website for tracking flu
8. Johnson Controls deals for asset-tracking software
9. RFID system aids hospital in tracking assets
10. State tracks more angel investment, at least $19M last year
11. On track with the FDA -- But what about your coverage and reimbursement strategy?